The Big Biosimilars Questions: Will Senate Get Answers?
This article was originally published in Scrip
When a Senate subcommittee of the Health, Education, Labor and Pensions (HELP) panel calls Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, to testify on Sept. 17, AbbVie is hoping lawmakers will get to the bottom of why the agency did not require Novartis and its Sandoz unit to identify in the labeling of Zarxio (filgrastim-sndz) the product is a biosimilar and did not clearly state the drug had not been found to be interchangeable – something regulators had earlier said in a draft guidance was "necessary" to declare.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.